Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents

Por Untch, Michael, von Minckwitz, Gunter
Publicado em 2009

Neoadjuvant Treatment of Breast Cancer

Por Untch, Michael, von Minckwitz, Gunter
Publicado em 2011

Neoadjuvant Therapy – What Have We Achieved in the Last 20 Years?

Por Huober, Jens, von Minckwitz, Gunter
Publicado em 2011

Pathway-Oriented Concepts in Adjuvant and Neoadjuvant Breast Cancer Therapy

Por von Minckwitz, Gunter, Fontanella, Caterina
Publicado em 2013

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design

Por Pirvulescu, Cristina, von Minckwitz, Gunter, Loibl, Sibylle
Publicado em 2008

Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression

Por Pirvulescu, Christina, Uhlig, Mathias, von Minckwitz, Gunter
Publicado em 2008

Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer

Por Janni, Wolfgang, von Minckwitz, Gunter, Möbus, Volker, Nitz, Ulrike
Publicado em 2008

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

Por Issa-Nummer, Yasmin, Loibl, Sibylle, von Minckwitz, Gunter, Denkert, Carsten
Publicado em 2014

Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone

Por Uleer, Christoph, Yazdan-Pourfard, Jasmin, Holland, Bernhard, Karl-Friedrich, Bürrig, Moisidis-Tesch, Christina, von Minckwitz, Gunter
Publicado em 2012

Male Breast Cancer: 20-Year Survival Data for Post-Mastectomy Radiotherapy

Por Eggemann, Holm, Ignatov, Atanas, Stabenow, Roland, von Minckwitz, Gunter, Röhl, Friedrich Wilhelm, Hass, Peter, Costa, Serban-Dan
Publicado em 2013

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer-...

Por Loibl, Sibylle, Skacel, Tomas, Nekljudova, Valentina, Lück, Hans Joachim, Schwenkglenks, Matthias, Brodowicz, Thomas, Zielinski, Christoph, von Minckwitz, Gunter
Publicado em 2011

Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts

Por Denkert, Carsten, Sinn, Bruno Valentin, Issa, Yasmin, Maria Müller, Berit, Maisch, Andrea, Untch, Michael, von Minckwitz, Gunter, Loibl, Sibylle
Publicado em 2011

Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer

Por Reinisch, Mattea, von Minckwitz, Gunter, Harbeck, Nadia, Janni, Wolfgang, Kümmel, Sherko, Kaufmann, Manfred, Elling, Dirk, Nekljudova, Valentina, Loibl, Sibylle
Publicado em 2013

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

Por Miquel-Cases, Anna, Retèl, Valesca P., Lederer, Bianca, von Minckwitz, Gunter, Steuten, Lotte M. G., van Harten, Wim H.
Publicado no PLoS One (2016)

Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’

Por Jackisch, Christian, Untch, Michael, Chatsiproios, Dimitrios, Lamparter, Christiane, Overkamp, Friedrich, Lichtenegger, Werner, Rönsberg, Wolfgang, Thomssen, Christoph, von Minckwitz, Gunter, Albert, Ute-Susann
Publicado em 2008

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

Por Loibl, Sibylle, Doering, Gabriele, Müller, Lothar, Grote-Metke, Albert, Müller, Roberto, Tomé, Oliver, Wiest, Wolfgang, Maisch, Andrea, Nekljudova, Valentina, von Minckwitz, Gunter
Publicado em 2011

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

Por Loibl, Sibylle, von Minckwitz, Gunter, Harbeck, Nadia, Janni, Wolfgang, Elling, Dirk, Kaufmann, Manfred, Eggemann, Holm, Nekljudova, Valentina, Sommer, Harald, Kiechle, Marion, Kümmel, Sherko
Publicado em 2008

Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer

Por Harbeck, Nadia, Schmitt, Manfred, Vetter, Martina, Krol, Janna, Paepke, Daniela, Uhlig, Mathias, Paepke, Stefan, Jänicke, Fritz, Geurts-Moespot, Anneke, von Minckwitz, Gunter, Sweep, Fred, Thomssen, Christoph
Publicado em 2008

Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study

Por Halfter, Kathrin, Ditsch, Nina, Kolberg, Hans-Christian, Fischer, Holger, Hauzenberger, Tanja, von Koch, Franz Edler, Bauerfeind, Ingo, von Minckwitz, Gunter, Funke, Ilona, Crispin, Alexander, Mayer, Barbara
Publicado no BMC Cancer (2015)

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study – SOFIA†

Por Loibl, Sibylle, Rokitta, Dennis, Conrad, Bettina, Harbeck, Nadia, Wüllner, Michaela, Warm, Mathias, Schwedler, Kathrin, Gerber, Bernd, Schrader, Iris, Eidtmann, Holger, Mehta, Keyur, Fuhr, Uwe, von Minckwitz, Gunter
Publicado em 2014